A SIMPLE KEY FOR ABBV-744 FOR TARGETED CANCER THERAPY TREATMENT UNVEILED

In Section A, individuals will receive different doses and schedules of oral ABBV-744 tablet to determine Secure dosing program. More individuals will likely be enrolled in the identified monotherapy dosign routine. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C, participa